Enhancing the Therapeutic Potential of Mesenchymal Stromal Cell-Based Therapies with an Anti-Fibrotic Agent for the Treatment of Chronic Kidney Disease
Chronic kidney disease (CKD) affects 1 in 10 members of the general population, placing these patients at an increasingly high risk of kidney failure. Despite the significant burden of CKD on various healthcare systems, there are no effective cures that reverse or even halt its progression. In recen...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-05-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/23/11/6035 |
| _version_ | 1797493185240367104 |
|---|---|
| author | Yifang Li Sharon D. Ricardo Chrishan S. Samuel |
| author_facet | Yifang Li Sharon D. Ricardo Chrishan S. Samuel |
| author_sort | Yifang Li |
| collection | DOAJ |
| description | Chronic kidney disease (CKD) affects 1 in 10 members of the general population, placing these patients at an increasingly high risk of kidney failure. Despite the significant burden of CKD on various healthcare systems, there are no effective cures that reverse or even halt its progression. In recent years, human bone-marrow-derived mesenchymal stromal cells (BM-MSCs) have been recognised as a novel therapy for CKDs, owing to their well-established immunomodulatory and tissue-reparative properties in preclinical settings, and their promising safety profile that has been demonstrated in patients with CKDs from several clinical trials. However, renal fibrosis (scarring), a hallmark of CKD, has been shown to impair the viability and functionality of BM-MSCs post-transplantation. This has suggested that BM-MSCs might require a pre-treatment or adjunct therapy that can enhance the viability and therapeutic efficacy of these stromal cells in chronic disease settings. To address this, recent studies that have combined BM-MSCs with the anti-fibrotic drug serelaxin (RLX), have demonstrated the enhanced therapeutic potential of this combination therapy in normotensive and hypertensive preclinical models of CKD. In this review, a critical appraisal of the preclinical data available on the anti-fibrotic and renoprotective actions of BM-MSCs or RLX alone and when combined, as a treatment option for normotensive vs. hypertensive CKD, is discussed. |
| first_indexed | 2024-03-10T01:16:23Z |
| format | Article |
| id | doaj.art-b4db639907a24ed28dc764ec54ce6d87 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T01:16:23Z |
| publishDate | 2022-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-b4db639907a24ed28dc764ec54ce6d872023-11-23T14:08:33ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672022-05-012311603510.3390/ijms23116035Enhancing the Therapeutic Potential of Mesenchymal Stromal Cell-Based Therapies with an Anti-Fibrotic Agent for the Treatment of Chronic Kidney DiseaseYifang Li0Sharon D. Ricardo1Chrishan S. Samuel2Cardiovascular Disease Program, Department of Pharmacology, Monash Biomedicine Discovery Institute, Monash University, Melbourne, VIC 3800, AustraliaDevelopment and Stem Cells Program, Department of Pharmacology, Monash Biomedicine Discovery Institute, Monash University, Melbourne, VIC 3800, AustraliaCardiovascular Disease Program, Department of Pharmacology, Monash Biomedicine Discovery Institute, Monash University, Melbourne, VIC 3800, AustraliaChronic kidney disease (CKD) affects 1 in 10 members of the general population, placing these patients at an increasingly high risk of kidney failure. Despite the significant burden of CKD on various healthcare systems, there are no effective cures that reverse or even halt its progression. In recent years, human bone-marrow-derived mesenchymal stromal cells (BM-MSCs) have been recognised as a novel therapy for CKDs, owing to their well-established immunomodulatory and tissue-reparative properties in preclinical settings, and their promising safety profile that has been demonstrated in patients with CKDs from several clinical trials. However, renal fibrosis (scarring), a hallmark of CKD, has been shown to impair the viability and functionality of BM-MSCs post-transplantation. This has suggested that BM-MSCs might require a pre-treatment or adjunct therapy that can enhance the viability and therapeutic efficacy of these stromal cells in chronic disease settings. To address this, recent studies that have combined BM-MSCs with the anti-fibrotic drug serelaxin (RLX), have demonstrated the enhanced therapeutic potential of this combination therapy in normotensive and hypertensive preclinical models of CKD. In this review, a critical appraisal of the preclinical data available on the anti-fibrotic and renoprotective actions of BM-MSCs or RLX alone and when combined, as a treatment option for normotensive vs. hypertensive CKD, is discussed.https://www.mdpi.com/1422-0067/23/11/6035chronic kidney diseasefibrosisbone-marrow-derived mesenchymal stromal cellsrelaxinwound repairangiogenesis |
| spellingShingle | Yifang Li Sharon D. Ricardo Chrishan S. Samuel Enhancing the Therapeutic Potential of Mesenchymal Stromal Cell-Based Therapies with an Anti-Fibrotic Agent for the Treatment of Chronic Kidney Disease International Journal of Molecular Sciences chronic kidney disease fibrosis bone-marrow-derived mesenchymal stromal cells relaxin wound repair angiogenesis |
| title | Enhancing the Therapeutic Potential of Mesenchymal Stromal Cell-Based Therapies with an Anti-Fibrotic Agent for the Treatment of Chronic Kidney Disease |
| title_full | Enhancing the Therapeutic Potential of Mesenchymal Stromal Cell-Based Therapies with an Anti-Fibrotic Agent for the Treatment of Chronic Kidney Disease |
| title_fullStr | Enhancing the Therapeutic Potential of Mesenchymal Stromal Cell-Based Therapies with an Anti-Fibrotic Agent for the Treatment of Chronic Kidney Disease |
| title_full_unstemmed | Enhancing the Therapeutic Potential of Mesenchymal Stromal Cell-Based Therapies with an Anti-Fibrotic Agent for the Treatment of Chronic Kidney Disease |
| title_short | Enhancing the Therapeutic Potential of Mesenchymal Stromal Cell-Based Therapies with an Anti-Fibrotic Agent for the Treatment of Chronic Kidney Disease |
| title_sort | enhancing the therapeutic potential of mesenchymal stromal cell based therapies with an anti fibrotic agent for the treatment of chronic kidney disease |
| topic | chronic kidney disease fibrosis bone-marrow-derived mesenchymal stromal cells relaxin wound repair angiogenesis |
| url | https://www.mdpi.com/1422-0067/23/11/6035 |
| work_keys_str_mv | AT yifangli enhancingthetherapeuticpotentialofmesenchymalstromalcellbasedtherapieswithanantifibroticagentforthetreatmentofchronickidneydisease AT sharondricardo enhancingthetherapeuticpotentialofmesenchymalstromalcellbasedtherapieswithanantifibroticagentforthetreatmentofchronickidneydisease AT chrishanssamuel enhancingthetherapeuticpotentialofmesenchymalstromalcellbasedtherapieswithanantifibroticagentforthetreatmentofchronickidneydisease |